[{"id":"a8d426ea-8842-4fc1-bfee-96024bf6f5ae","acronym":"APVO436","url":"https://clinicaltrials.gov/study/NCT03647800","created_at":"2021-05-26T19:57:54.811Z","updated_at":"2024-07-02T16:36:17.299Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Patients With AML or MDS","source_id_and_acronym":"NCT03647800 - APVO436","lead_sponsor":"Aptevo Research and Development LLC","biomarkers":" FLT3 • RUNX1 • ASXL1 • IL3RA","pipe":" | ","alterations":" ASXL1 mutation • CD123 positive • IL3RA positive","tags":["FLT3 • RUNX1 • ASXL1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASXL1 mutation • CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipletamig (APVO436)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 06/15/2023","study_completion_date":" 06/15/2023","last_update_posted":"2022-02-10"},{"id":"3fedea47-3322-47fb-bf06-bb20557b31c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973618","created_at":"2023-08-14T10:11:06.153Z","updated_at":"2024-07-02T16:36:20.014Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML","source_id_and_acronym":"NCT04973618","lead_sponsor":"Aptevo Therapeutics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • mipletamig (APVO436)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2021-12-01"}]